Resistance to BRAF inhibitors drives melanoma sensitivity to Chk1 inhibition

Resistance to BRAF inhibitors drives melanoma sensitivity to Chk1 inhibition

BRAF inhibitor-resistant melanomas (BRAFiR) acquire (epi)genetic and functional alterations that enable them to evade alternative treatments. Identifying these alterations is critical to advancing treatment strategies. Here, we explored the effect of Chk1 inhibition (Chk1i) on BRAFiR cells, revealin...

Full description

Saved in:
Bibliographic Details
Main Authors: Danielle G. Carvalho, Juliana C.N. Kenski, Daniel A. Moreira, Matheus A. Rajão, Oscar Krijgsman, Carolina Furtado, Mariana Boroni, João P.B. Viola, Daniel S. Peeper, Patricia A. Possik
Format: Article
Language:English
Published: Elsevier 2025-07-01
Series:Pharmacological Research
Subjects:
Melanoma
BRAF
Targeted therapy
Replication Stress
Online Access:http://www.sciencedirect.com/science/article/pii/S1043661825002221
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items